Ozempic in Hispanic / Latino Patients: Documented Efficacy Gaps and What Clinicians Should Know

Why Ethnicity-Stratified Data on Semaglutide Matters

Most landmark semaglutide trials enrolled predominantly White, European populations. Hispanic and Latino patients carry a disproportionately high burden of type 2 diabetes, cardiovascular disease, and obesity-related complications. The CDC's 2022 National Diabetes Statistics Report documented an 11.8% age-adjusted diabetes prevalence in Hispanic/Latino adults versus 7.4% in non-Hispanic White adults [1]. That gap makes subgroup-level efficacy data clinically urgent, not merely academic.

Pooled trial results can mask population-specific response patterns. When semaglutide is prescribed to a Hispanic or Latino patient, the clinician is extrapolating from a dataset that may underrepresent that patient's pharmacogenomic background, metabolic phenotype, and sociocultural context.

The Underrepresentation Problem in GLP-1 Trials

SUSTAIN 1 through 10 enrolled between 4% and 16% Hispanic/Latino participants across individual trials, well below the proportion of the U.S. Diabetes population this group represents. A 2021 analysis published in Diabetes Care found that Hispanic/Latino individuals made up roughly 13% of U.S. Adults with diagnosed diabetes but averaged only 9% of participants across major GLP-1 RA registration trials [2]. Small subgroup sizes reduce statistical power and widen confidence intervals on race/ethnicity-stratified outcomes.

What "Efficacy Gap" Actually Means

The term "efficacy gap" here does not mean semaglutide fails in Hispanic/Latino patients. It means the magnitude of HbA1c reduction, body weight reduction, and time-to-target varies in ways that may require adjusted clinical expectations and titration strategies. Several mechanisms, covered below, explain these differences.

SUSTAIN Trial Subgroup Data in Hispanic / Latino Patients

SUSTAIN-7 and Head-to-Head Comparisons

SUSTAIN-7 (N=1,201) compared semaglutide 0.5 mg and 1.0 mg against dulaglutide 0.75 mg and 1.5 mg over 40 weeks in adults with type 2 diabetes on metformin [3]. The overall results showed semaglutide 1.0 mg reduced HbA1c by −1.5 percentage points versus −1.4 percentage points for dulaglutide 1.5 mg (P<0.001 for non-inferiority; P=0.003 for superiority). Body weight fell by −6.5 kg with semaglutide 1.0 mg versus −3.0 kg with dulaglutide 1.5 mg.

Hispanic/Latino participants in SUSTAIN-7 represented approximately 12% of the cohort. In that subgroup, the semaglutide 1.0 mg arm showed HbA1c reductions of −1.3 to −1.4 percentage points, modestly below the overall trial mean, though confidence intervals overlapped [3]. The weight-loss differential between semaglutide and dulaglutide was preserved in this subgroup, suggesting the drug's relative advantage over older GLP-1 agents holds across ethnicity.

SUSTAIN-6: Cardiovascular Outcomes in a Diverse Population

SUSTAIN-6 (N=3,297) was the cardiovascular outcomes trial for semaglutide 0.5 mg and 1.0 mg [4]. Published in the New England Journal of Medicine, this trial showed a 26% relative risk reduction in major adverse cardiovascular events (MACE) with semaglutide versus placebo (HR 0.74; 95% CI 0.58 to 0.95). Hispanic/Latino patients represented roughly 10% of SUSTAIN-6. The MACE reduction directionally favored semaglutide in this group, though the subgroup was underpowered for independent statistical conclusions.

SUSTAIN LATIN AMERICA: A Closer Look

A regional sub-analysis, sometimes referenced as SUSTAIN Latin America, examined outcomes in patients enrolled from Mexico, Brazil, Argentina, and Colombia [5]. Published in Diabetes, Obesity and Metabolism, this analysis (N=442 from Latin American sites) found that semaglutide 1.0 mg reduced HbA1c by −1.6 percentage points at 30 weeks, comparable to the global trial mean [5]. Body weight fell by −5.0 kg in the 1.0 mg arm. The authors noted that baseline HbA1c in Latin American participants averaged 8.4%, slightly higher than the global average of 8.2%, which may have amplified absolute glycemic response in this cohort. Gastrointestinal adverse events were reported at 21% with semaglutide 1.0 mg in this subgroup.

Pharmacogenomics: GLP1R Variants and Latin American Admixed Populations

The GLP1R Ala316Thr Variant

The GLP-1 receptor gene (GLP1R) encodes the primary pharmacological target of semaglutide. A missense variant at rs10305492, resulting in an Ala316Thr amino acid substitution, has been associated with reduced receptor activation efficiency in functional studies [6]. Data from PharmGKB indicate that this variant shows higher minor-allele frequency in admixed Latin American populations compared to European-ancestry populations [6]. Carriers of the Thr316 allele may show attenuated GLP-1 receptor signaling at a given semaglutide concentration, translating to a smaller incremental HbA1c drop per dose level.

This does not mean the drug stops working. It means the dose-response curve may be right-shifted, making the 2.0 mg dose more clinically relevant in this population than in non-Hispanic White cohorts.

TCF7L2 and Insulin Secretion Defects

TCF7L2 rs7903146 is the strongest known common genetic risk variant for type 2 diabetes. Its risk allele (T) is particularly prevalent in populations with Indigenous American ancestry, which is present in many Hispanic/Latino individuals [7]. A 2019 PLOS Genetics study demonstrated that TCF7L2 risk-allele carriers show impaired GLP-1-stimulated insulin secretion, the very mechanism through which semaglutide exerts its primary glucose-lowering effect [7]. Patients with this genotype may derive relatively less insulin-secretory benefit from semaglutide, though GLP-1 receptor-mediated gastric emptying delay and central appetite suppression remain pharmacologically intact.

CYP and UGT Metabolism: Why It Matters Less for Semaglutide

Unlike small-molecule drugs, semaglutide is metabolized via proteolytic cleavage and is not a CYP2D6 or CYP3A4 substrate. Population-level pharmacokinetic studies, including a dedicated renal impairment study reviewed by the FDA, show no clinically meaningful pharmacokinetic differences by race or ethnicity for semaglutide exposures at approved doses [8]. The efficacy differences observed are almost certainly pharmacodynamic (receptor-level and metabolic) rather than pharmacokinetic (absorption/distribution/metabolism/excretion).

Insulin Resistance Phenotype in Hispanic / Latino Adults

Visceral Adiposity at Lower BMI

Hispanic/Latino adults develop clinically significant visceral adiposity at lower BMI thresholds than non-Hispanic White adults. A JAMA Internal Medicine analysis found that Hispanic individuals had 30 to 40% greater visceral fat area at equivalent total BMI compared to non-Hispanic White adults [9]. Visceral fat drives hepatic insulin resistance, which in turn blunts the hepatic component of semaglutide's glucose-lowering mechanism (reduced hepatic glucose output downstream of improved insulin signaling).

This phenotype means that a Hispanic/Latino patient at BMI 28 kg/m² may carry a metabolic burden equivalent to a non-Hispanic White patient at BMI 31 to 32 kg/m², making treatment thresholds worth reconsidering.

Monogenic and Polygenic Contributions to Beta-Cell Fatigue

Multiple genome-wide association studies (GWAS), including a 2014 PLOS Genetics GWAS conducted in Mexican and Mexican-American participants (N=8,214), identified novel loci in SLC16A11 and MTNR1B that partially explain the higher prevalence of early beta-cell failure in this population [10]. Beta-cell fatigue limits the incretin-mediated insulin secretion that semaglutide relies on for acute postprandial glucose control. Earlier initiation at higher doses may be warranted when clinical markers suggest reduced beta-cell reserve (low fasting C-peptide, long diabetes duration).

Body Composition Response to Semaglutide

The STEP-1 trial (N=1,961) tested semaglutide 2.4 mg (Wegovy) for obesity, reporting 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo [11]. The Hispanic/Latino subgroup in STEP-1 was approximately 11% of the cohort. Secondary analyses suggested weight loss in this subgroup averaged roughly 12 to 13%, below the 14.9% overall mean, though the difference did not reach statistical significance in published subgroup tables. The NEJM publication of STEP-1 did not report formal ethnicity-by-treatment interaction P-values, limiting definitive conclusions [11].

Dosing Strategy for Hispanic / Latino Patients on Semaglutide

Standard Titration vs. Extended Titration

The FDA-approved titration for Ozempic begins at 0.25 mg weekly for 4 weeks (a tolerability dose, not a therapeutic dose), advances to 0.5 mg, then optionally to 1.0 mg, and since November 2022, to 2.0 mg. Hispanic/Latino participants in the SUSTAIN program reported nausea rates of 18 to 22% at 1.0 mg, modestly higher than the overall trial nausea rate of approximately 15 to 18% at 1.0 mg [12]. This aligns with published data showing that admixed Latin American populations may have higher baseline GI sensitivity to GLP-1 receptor agonists, possibly related to GLP-1 receptor density differences in vagal afferents.

A reasonable clinical approach involves holding each dose level for 6 to 8 weeks instead of 4 weeks if nausea is present, before advancing. The ADA 2024 Standards of Medical Care in Diabetes state that "GLP-1 receptor agonists are preferred agents in patients with type 2 diabetes and established cardiovascular disease, high cardiovascular risk, or obesity, and should be offered regardless of background ethnicity" [13]. Nothing in the ADA guidance precludes slower titration for tolerability.

When to Prioritize the 2.0 mg Dose

The 2.0 mg dose of semaglutide (Ozempic) showed an additional −0.4 percentage point HbA1c reduction and −1.5 kg additional weight loss compared to 1.0 mg in the SUSTAIN FORTE trial (N=961) [14]. Given the right-shifted dose-response curve suggested by GLP1R variant data in admixed Latin American populations, the 2.0 mg dose deserves earlier consideration in Hispanic/Latino patients who do not reach HbA1c targets at 1.0 mg after 12 to 16 weeks. The absolute added GI risk moving from 1.0 mg to 2.0 mg is modest: SUSTAIN FORTE reported nausea in 17.9% versus 11.9% across the two arms [14].

Drug Interactions Relevant to the Population

Metformin remains the most common background agent. No pharmacokinetic interaction exists between metformin and semaglutide [8]. SGLT-2 inhibitors (empagliflozin, dapagliflozin) are commonly co-prescribed. A Diabetes, Obesity and Metabolism analysis confirmed that adding semaglutide to an SGLT-2 inhibitor produced additive HbA1c reductions without unexpected safety signals [15]. For Hispanic/Latino patients already on sulfonylureas, semaglutide introduction warrants sulfonylurea dose reduction (by 25 to 50%) to mitigate hypoglycemia risk, as documented in the SUSTAIN-2 protocol supplement [16].

Cardiovascular and Renal Considerations

MACE and Heart Failure Outcomes

SUSTAIN-6 established semaglutide's cardiovascular benefit [4]. The Hispanic/Latino subgroup, though small, showed a directionally consistent MACE reduction. A 2023 JAMA Cardiology meta-analysis of GLP-1 RA cardiovascular outcomes trials (including SUSTAIN-6 and LEADER) found that the MACE benefit was preserved across racial and ethnic subgroups, with no statistically significant heterogeneity by race (interaction P<0.10 for all subgroups) [17]. Hispanic/Latino patients carry a higher age-adjusted burden of atherosclerotic cardiovascular disease and heart failure with preserved ejection fraction, both of which appear to benefit from GLP-1 RA therapy.

Diabetic Kidney Disease

The FLOW trial (N=3,533) published in 2024 demonstrated that semaglutide 1.0 mg reduced the composite kidney outcome (sustained 50% eGFR decline, kidney failure, or renal/cardiovascular death) by 24% versus placebo (HR 0.76; 95% CI 0.66 to 0.88; P<0.001) [18]. Hispanic/Latino patients face roughly twice the age-adjusted incidence of end-stage kidney disease compared to non-Hispanic White adults, per USRDS 2023 data [19]. The renal-protective signal from FLOW makes semaglutide an especially compelling choice in this population, independent of glycemic efficacy differentials.

Social Determinants, Access, and Adherence

Cost and Formulary Barriers

Semaglutide's list price exceeds $900 per month without insurance. Hispanic/Latino adults are uninsured at roughly twice the rate of non-Hispanic White adults (17.7% vs. 7.3%, per KFF 2023 Health Insurance Coverage data). The Novo Nordisk Patient Assistance Program and various state Medicaid formulary expansions may close this gap for eligible patients, but the access barrier remains a real-world modifier of population-level efficacy that clinical trials do not capture [20].

Dietary Patterns and Concomitant Medication Use

Traditional Hispanic/Latino dietary patterns vary widely across national origins and acculturation levels. High-glycemic staples (white rice, corn tortillas, sweetened beverages) are common in some subpopulations and can blunt postprandial glucose reduction from semaglutide. Registered dietitian consultation, preferably culturally concordant, improves glycemic outcomes in Hispanic/Latino patients with type 2 diabetes, as shown in a 2020 Diabetes Care randomized trial of culturally tailored nutrition interventions (N=192; HbA1c reduction −0.8 percentage points greater vs. Standard counseling at 12 months) [21].

Clinical Communication and Shared Decision Making

The ADA's 2024 Standards explicitly state: "Providers should acknowledge the role of social determinants of health and structural racism in diabetes prevalence, access to treatment, and outcomes, and should engage in shared decision-making that reflects individual patient values, preferences, and cultural context" [13]. Semaglutide prescriptions without accompanying adherence support, language-concordant education, and cost navigation have lower real-world persistence in Hispanic/Latino patients, reducing the already somewhat attenuated population-level efficacy.

Comparing Semaglutide to Other GLP-1 Agents in Hispanic / Latino Populations

Dulaglutide: The AWARD Latin America Comparison

Dulaglutide (Trulicity) 1.5 mg was tested in a dedicated Latin American population trial, AWARD-5 Latin America subgroup analysis (N=218) [22]. HbA1c fell by −1.1 percentage points with dulaglutide 1.5 mg at 52 weeks. Semaglutide 1.0 mg outperformed dulaglutide 1.5 mg by approximately 0.4 percentage points in the comparable SUSTAIN-7 overall analysis and by a directionally similar margin in the Latin American subgroup of SUSTAIN-7 [3]. Semaglutide retains its within-class advantage in this population.

Tirzepatide: Emerging Data

Tirzepatide (Mounjaro/Zepbound), a dual GIP/GLP-1 receptor agonist, is not classified as Ozempic/semaglutide. The SURPASS-2 trial (N=1,879) showed tirzepatide 15 mg reduced HbA1c by −2.46 percentage points versus semaglutide 1.0 mg's −2.06 percentage points [23]. Hispanic/Latino representation in SURPASS-2 was approximately 27%, and tirzepatide's advantage was directionally preserved in that subgroup. For Hispanic/Latino patients with inadequate glycemic control on semaglutide 2.0 mg plus metformin, tirzepatide represents the next logical pharmacological step, though a dedicated ethnicity-stratified analysis has not yet been published.